Ranbaxy Excludes One-off Gains In Altered Sales Guidance As Guessing Game Continues On Valsartan
This article was originally published in PharmAsia News
Executive Summary
The Indian drug maker came out with subdued third quarter numbers in the face of adverse conditions in its home market. However, Ranbaxy has kept its hopes pinned on potential upsides in the U.S. from products like valsartan.
You may also be interested in...
Ranbaxy’s Ongoing Issues With FDA Continue Novartis Windfall With Diovan
Ranbaxy’s newest manufacturing site at Mohali, India, is prohibited by FDA from shipping products to the U.S., further delaying approval of generic valsartan. Novartis has recently revised its sales guidance due to lower than expected generic sales erosion in the U.S. this year.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.